Massachusetts General Hospital SC-5 is a clinical research site located in Boston, Massachusetts, United States 02114.
Crixeo Health Trust Score: 61/100 (FAIR). This profile has not yet been claimed by the site owner.
Massachusetts General Hospital SC-5 has participated in 2 clinical trials with 1 currently active.
Therapeutic areas: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Gastric Cancer.
Sponsors: Novartis Pharmaceuticals.
Trust Score: 61/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Massachusetts General Hospital SC-5 has a Crixeo Trust Score of 61/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Massachusetts General Hospital SC-5 has 2 clinical trials on record, with 1 currently active. Their work covers HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Gastric Cancer.
Massachusetts General Hospital SC-5 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.